AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9428829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate
Number of subjects: 193
Study 8512094 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl
Number of subjects: 121
Study 8512094 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane/nitrous oxide
Number of subjects: 121
Study 8512094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl/nitrous oxide
Number of subjects: 121
Study 3730231 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 2.1 MAC
Number of subjects: 0
Study 3730231 — intervention group
Group type: COMPARATOR
Intervention: Halothane 1.2 MAC
Number of subjects: 0
Study 29848613 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants of uncertain significance
Number of subjects: 289
Study 29848613 — intervention group
Group type: EXPERIMENTAL
Intervention: Possibly pathogenic result
Number of subjects: 289
Study 29848613 — intervention group
Group type: EXPERIMENTAL
Intervention: Single uncertain result
Number of subjects: 289
Study 27736851 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 114
Study 27736851 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux en Y gastric bypass (LRYGB)
Number of subjects: 114
Study 27736851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LSG and LRYGB
Number of subjects: 114
Study 25516885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohybrid resin composite (Excite/Tetric EvoCeram)
Number of subjects: 52
Study 25516885 — intervention group
Group type: COMPARATOR
Intervention: Conventional hybrid resin composite (Excite/Tetric Ceram)
Number of subjects: 52
Study 22588236 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringoplasty with cortical mastoidectomy (Group A)
Number of subjects: 320
Study 22588236 — intervention group
Group type: COMPARATOR
Intervention: Myringoplasty only (Group B)
Number of subjects: 320
Study 20433700 — intervention group
Group type: EXPERIMENTAL
Intervention: ProActive intervention (physical activity promotion)
Number of subjects: 321
Study 20433700 — intervention group
Group type: COMPARATOR
Intervention: Baseline demographic, clinical, psychosocial and behavioural variables
Number of subjects: 321
Study 18698246 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) photodynamic therapy
Number of subjects: 81
Study 18698246 — intervention group
Group type: COMPARATOR
Intervention: Control (lesion-specific treatment, 83% cryotherapy)
Number of subjects: 81
Study 15713351 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 21
Study 15713351 — intervention group
Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 21
Study 12075764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, killed enterotoxigenic Escherichia coli plus cholera toxin B-subunit vaccine
Number of subjects: 64
Study 9524014 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 2 x 2.5 mg
Number of subjects: 18
Study 9524014 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 7706153 — intervention group
Group type: EXPERIMENTAL
Intervention: constructed‐response interactive videodisc instruction
Number of subjects: 101
Study 7706153 — intervention group
Group type: COMPARATOR
Intervention: click‐to‐continue or passive viewing formats
Number of subjects: 101
Study 7706153 — intervention group
Group type: EXPERIMENTAL
Intervention: constructed answers
Number of subjects: 101
Study 2748470 — intervention group
Group type: EXPERIMENTAL
Intervention: Diapers with absorbent polymer
Number of subjects: 150
Study 2748470 — intervention group
Group type: COMPARATOR
Intervention: Fluff diapers
Number of subjects: 150
Study 200357 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field irradiation and further chemotherapy
Number of subjects: 31
Study 200357 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic whole-brain irradiation
Number of subjects: 31
Study 200357 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 31
Study 31811839 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mg vaginal dinoprostone
Number of subjects: 200
Study 31811839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 30591470 — intervention group
Group type: EXPERIMENTAL
Intervention: Data accuracy assessment from the Regional Head and Neck Register
Number of subjects: 73
Study 30591470 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up data assessment from the Regional Head and Neck Register
Number of subjects: 73
Study 27503233 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous secretors (SeSe)
Number of subjects: 112
Study 27503233 — intervention group
Group type: COMPARATOR
Intervention: Non-secretors (sese)
Number of subjects: 112
Study 27503233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal, viral and non‐dominant bacterial components of the microbiome
Number of subjects: 112
Study 25555163 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% 1RM blood-flow restriction at 40% pressure
Number of subjects: 0
Study 25555163 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% 1RM blood-flow restriction
Number of subjects: 0
Study 25555163 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% 1RM blood-flow restriction at 50% pressure
Number of subjects: 0
Study 25555163 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% 1RM blood-flow restriction at 60% pressure
Number of subjects: 0
Study 25555163 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load condition
Number of subjects: 0
Study 25555163 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% 1RM to failure
Number of subjects: 0
Study 23620429 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital color grading of fundus photographs
Number of subjects: 4203
Study 23620429 — intervention group
Group type: COMPARATOR
Intervention: Historical film-based images
Number of subjects: 4203
Study 23620429 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS2-AREDS concordance for temporal drift
Number of subjects: 4203
Study 21679357 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported speed treadmill training exercise program (SSTTEP)
Number of subjects: 26
Study 21679357 — intervention group
Group type: COMPARATOR
Intervention: Exercise (strengthening)
Number of subjects: 26
Study 19539101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg BID
Number of subjects: 1
Study 19539101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 16931867 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose+fructose solution
Number of subjects: 0
Study 16931867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution
Number of subjects: 0
Study 16931867 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0
Study 15383183 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (300.5 mg/day mean dose, maximum 686.0 mg/day)
Number of subjects: 426
Study 15383183 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 426
Study 11023137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber (HF) diet
Number of subjects: 63
Study 11023137 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber (LF) diet
Number of subjects: 63
Study 9012298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) infusion at 1.5 micrograms/kg/min
Number of subjects: 10
Study 9012298 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 10
Study 1415377 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) treatment at Hb 9 g/dl
Number of subjects: 12
Study 1415377 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) treatment at Hb 12 g/dl
Number of subjects: 12
Study 3892745 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomoses and skin closures
Number of subjects: 69
Study 3892745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstapled anastomoses
Number of subjects: 69
Study 3892745 — intervention group
Group type: COMPARATOR
Intervention: Sutured anastomoses with sutured skin closure
Number of subjects: 69
Study 3892745 — intervention group
Group type: COMPARATOR
Intervention: Stapled skin closure
Number of subjects: 69
Study 3892745 — intervention group
Group type: COMPARATOR
Intervention: Stapled closure in guinea pig model
Number of subjects: 69
Study 30115264 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (PreOp™; Nutricia, Erlangen, Germany)
Number of subjects: 120
Study 30115264 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative fasting
Number of subjects: 120
Study 27865182 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800mg/day with pitavastatin 2mg/day
Number of subjects: 241
Study 27865182 — intervention group
Group type: COMPARATOR
Intervention: Statin alone (control group)
Number of subjects: 241
Study 24788580 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-mediated home-based intervention (CHI)
Number of subjects: 51
Study 24788580 — intervention group
Group type: COMPARATOR
Intervention: Control (therapist visits without intervention)
Number of subjects: 51
Study 23219638 — intervention group
Group type: EXPERIMENTAL
Intervention: Laerdal circuit with PEEP 7.5 cmH(2)O
Number of subjects: 15
Study 23219638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson‐C circuit with PEEP 7.5 cmH(2)O
Number of subjects: 15
Study 23219638 — intervention group
Group type: COMPARATOR
Intervention: Laerdal circuit
Number of subjects: 15
Study 23219638 — intervention group
Group type: COMPARATOR
Intervention: Mapleson‐C circuit
Number of subjects: 15
Study 21576129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg bid
Number of subjects: 4628
Study 21576129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4628
Study 17949799 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pegylated liposomal doxorubicin (PLD) (30 mg/m2) plus i.v. carboplatin (AUC=5 mg/mL min) once every 4 weeks
Number of subjects: 61
Study 17949799 — intervention group
Group type: COMPARATOR
Intervention: i.v. carboplatin alone (AUC=5 mg/mL min) once every 4 weeks
Number of subjects: 61
Study 16815121 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch-based thickeners
Number of subjects: 5
Study 16815121 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum-based thickeners
Number of subjects: 5
Study 16815121 — intervention group
Group type: COMPARATOR
Intervention: Original beverages
Number of subjects: 5
Study 14550869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (test)
Number of subjects: 12
Study 14550869 — intervention group
Group type: COMPARATOR
Intervention: Propulsid (reference)
Number of subjects: 12
Study 11356997 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 11356997 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-intensity anticoagulation (target INR values: 2.5-3.5)
Number of subjects: 0
Study 11356997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity anticoagulation (target INR values: 1.1-1.6)
Number of subjects: 0
Study 8794442 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-DG (1.5 mg E2 for 24 days with 0.15 mg DG for the last 12 days followed by 1 placebo tablet for 4 days)
Number of subjects: 310
Study 8794442 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-NETA (2 mg E2 for 22 days with 1 mg NETA for the last 10 days followed by 1 mg E2 for 6 days)
Number of subjects: 310
Study 8794442 — intervention group
Group type: COMPARATOR
Intervention: E2-DG
Number of subjects: 310
Study 8794442 — intervention group
Group type: COMPARATOR
Intervention: E2-NETA
Number of subjects: 310
Study 1377306 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (20 mg single dose)
Number of subjects: 10
Study 1377306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg daily for 2 months)
Number of subjects: 10
Study 1377306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6740419 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-dur
Number of subjects: 0
Study 6740419 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphyllin Retard
Number of subjects: 0
Study 6740419 — intervention group
Group type: COMPARATOR
Intervention: Alcophyllin syrup
Number of subjects: 0
Study 3080291 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms bid
Number of subjects: 330
Study 3080291 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms bid
Number of subjects: 330
Study 3080291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 3080291 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including antacid use)
Number of subjects: 330
Study 3080291 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms
Number of subjects: 330
Study 3080291 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 330
Study 31262680 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM splints and patient‐specific osteosynthesis for maxillary positioning (Group 1)
Number of subjects: 18
Study 31262680 — intervention group
Group type: COMPARATOR
Intervention: Occlusal wafers fabricated on a semi‐adjustable articulator (Group 2)
Number of subjects: 18
Study 28786301 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 kVp, 10 mAs, with MBIR
Number of subjects: 120
Study 28786301 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp, 15 mAs, with MBIR
Number of subjects: 120
Study 28786301 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp, 10 mAs, with MBIR
Number of subjects: 120
Study 28786301 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp, 5 mAs, with MBIR
Number of subjects: 120
Study 28786301 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp, 25 mAs, with FBP reconstruction
Number of subjects: 120
Study 26888726 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative focus group discussions among biomedical scientists
Number of subjects: 3
Study 26888726 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior scientists
Number of subjects: 3
Study 26888726 — intervention group
Group type: EXPERIMENTAL
Intervention: PhD students and postdoctoral fellows
Number of subjects: 3
Study 26118148 — intervention group
Group type: EXPERIMENTAL
Intervention: FSS-AA T2DM (Family Support Scale Adapted for African American women with T2DM)
Number of subjects: 200
Study 26118148 — intervention group
Group type: EXPERIMENTAL
Intervention: FSS-AA T2DM
Number of subjects: 200
Study 23018440 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug conservation group
Number of subjects: 2206
Study 23018440 — intervention group
Group type: COMPARATOR
Intervention: Viral suppression group
Number of subjects: 2206
Study 23018440 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug conservation participants on fully suppressive ART
Number of subjects: 2206
Study 23018440 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug conservation participants who resumed ART
Number of subjects: 2206
Study 20197480 — intervention group
Group type: EXPERIMENTAL
Intervention: (1)H-MRSI-DCEMR examination and targeted samples on suspicious areas
Number of subjects: 180
Study 20197480 — intervention group
Group type: COMPARATOR
Intervention: Second random prostate biopsy
Number of subjects: 180
Study 20197480 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSI
Number of subjects: 180
Study 20197480 — intervention group
Group type: EXPERIMENTAL
Intervention: DCEMR
Number of subjects: 180
Study 20197480 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSI plus DCEMR
Number of subjects: 180
Study 18230235 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (WED)
Number of subjects: 0
Study 18230235 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (RT)
Number of subjects: 0
Study 18230235 — intervention group
Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 0
Study 16679825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Lycopene (3 mg/day), Lutein (3 mg/day), Beta-carotene (4.8 mg/day), Alpha-tocopherol (10 mg/day), Selenium (75 microg/day)
Number of subjects: 39
Study 16679825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Lycopene (6 mg/day), Beta-carotene (4.8 mg/day), Alpha-tocopherol (10 mg/day), Selenium (75 microg/day)
Number of subjects: 39
Study 16679825 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control (Group 3)
Number of subjects: 39
Study 12564742 — intervention group
Group type: EXPERIMENTAL
Intervention: talinolol (100 mg)
Number of subjects: 198
Study 12564742 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 mg)
Number of subjects: 198
Study 11200748 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in sarcoidosis patients (3.18 pg/ml)
Number of subjects: 28
Study 11200748 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL fluid from s.B in sarcoidosis patients (2.64 pg/ml)
Number of subjects: 28
Study 11200748 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in sarcoidosis patients (1.01 pg/ml)
Number of subjects: 28
Study 11200748 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL fluid from s.B in sarcoidosis patients (0.95 pg/ml)
Number of subjects: 28
Study 11200748 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in ND group (3.77 pg/ml)
Number of subjects: 28
Study 11200748 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in active sarcoidosis
Number of subjects: 28
Study 11200748 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL fluid from s.A in patients with indications to therapy (1.44 pg/ml)
Number of subjects: 28
Study 8825532 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam given two hours preoperatively
Number of subjects: 60
Study 8825532 — intervention group
Group type: COMPARATOR
Intervention: Placebo given two hours preoperatively
Number of subjects: 60
Study 8825532 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam given immediately before induction of anaesthesia
Number of subjects: 60
Study 1451729 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (50 mg orally)
Number of subjects: 6
Study 1451729 — intervention group
Group type: COMPARATOR
Intervention: Flecainide acetate (150 mg)
Number of subjects: 6
Study 6371535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (225 mg per day) and Aspirin (975 mg per day)
Number of subjects: 40
Study 6371535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6371535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole and Aspirin
Number of subjects: 40
Study 30254135 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg three times a day for 2 weeks, then 200 mg three times a day for a further 2 weeks
Number of subjects: 151
Study 30254135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 27177869 — intervention group
Group type: EXPERIMENTAL
Intervention: Skype-based online video chats and WhatsApp messages
Number of subjects: 18
Study 27177869 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study 25463450 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI)
Number of subjects: 30
Study 25463450 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fractional anisotropy of the left superior longitudinal fasciculus (SLF)
Number of subjects: 30
Study 25463450 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor vigilance test (PVT)
Number of subjects: 30
Study 22832637 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall-and-fracture risk assessment and management program including intensive targeted exercise
Number of subjects: 122
Study 22832637 — intervention group
Group type: COMPARATOR
Intervention: Usual care in a general geriatric unit
Number of subjects: 122
Study 21232664 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol for 6 months
Number of subjects: 960
Study 21232664 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel for 6 months
Number of subjects: 960
Study 21232664 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol at discharge
Number of subjects: 960
Study 21232664 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel at discharge
Number of subjects: 960
Study 21232664 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol at 6 months
Number of subjects: 960
Study 21232664 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel at 6 months
Number of subjects: 960
Study 19235536 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C Concentrate (PCC) replacement
Number of subjects: 0
Study 19235536 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapies
Number of subjects: 0
Study 17028293 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (300 U/kg), administered three times weekly starting 10 to 14 days before and continuing throughout radiotherapy.
Number of subjects: 154
Study 17028293 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered under double-blind conditions.
Number of subjects: 154
Study 15152816 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus minocycline microspheres
Number of subjects: 499
Study 15152816 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 499
Study 12793949 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 0
Study 12793949 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Synchronized Intermittent Mechanical Ventilation (SIMV)
Number of subjects: 0
Study 9588614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 161
Study 9588614 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphologic fitness
Number of subjects: 161
Study 9588614 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength fitness
Number of subjects: 161
Study 8019119 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 59